We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
"NMDA-Nitric Oxide-<sub>c</sub>GMP" pathway modulation in schizophrenia and depression: focus on sodium nitroprusside and ketamine.
- Authors
Baker, Glen B.; Dursun, Serdar M.
- Abstract
There is growing evidence demonstrating rapid effectiveness onset of action (within hours) of intravenous administration of ketamine in depression, treatment-resistant depression and bipolar depression. Published review in Science (2012) by Duman & Aghajanian calls this "perhaps the most important discovery in half a century." There is recent evidence published in JAMA Psychiatry (2013) by Hallak and colleagues provide evidence that sodium nitroprusside (SNP) given by intravenous route to patients diagnosed with schizophrenia improved psychosis within hours. Although the "precise" mechanism of action of both ketamine (in depression) and SNP (in schizophrenia) remain unclear but there is evidence indicating for the possible involvement of the "NMDA-Nitric Oxide-cGMP" pathway in mechanisms of action of these two rapidonset effective therapeutic interventions.
- Subjects
NITRIC oxide; SCHIZOPHRENIA treatment; THERAPEUTICS; MENTAL depression
- Publication
Klinik Psikofarmakoloji Bulteni, 2013, Vol 23, pS14
- ISSN
1017-7833
- Publication type
Abstract